Catalyst Wire Dossier Catalyst Wire Dossier

ABX-001

· Abalos Therapeutics GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABX-001, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies [Phase 1]

See pricing